The Market

MedTech: a structurally resilient sector with enduring industrial logic.

Medical technology is a roughly €640 billion industry worldwide at manufacturer prices. Europe is its second largest market, at about €170 billion, representing 26.4% of the global market and growing at around 6% a year over the past decade. But headline aggregates tell an investor very little on their own. Medical technology is not one market; it is a collection of loosely related markets. This page starts with the global picture, then looks at three European segments separately, on their own terms, with sources and uncertainty clearly stated.

Orthopaedics

US$68.5bn

Global forecast, 2030 · +4.8% a year

Diabetes care devices

US$61.2bn

Global forecast, 2030 · +12.3% a year

Cardiovascular devices

US$110.4bn

Global forecast, 2029 · +7.3% a year

~€640bn

~€170bn

6%

#2

1. THE global MARKET

A global industry, sized locally.

Medical technology is a roughly €640 billion industry worldwide at manufacturer prices — and almost none of that figure is useful until it is broken into the segments and geographies where capital is actually deployed.Europe accounts for 26.4% of the world medical device market, or about €170 billion. That share is the anchor: it implies a global market of roughly €640 billion in 2024 — MedTech Europe’s own two published figures, divided, rather than a third party’s aggregate. The United States is the single largest market at 46.4%; China and Japan together account for 11.2%.¹The industry does not grow with the economic cycle. It grows with demography, with the shift from acute events to multi-year chronic management, and with the clinical workforce shortage that makes any technology removing clinician time from a pathway non-optional. In Europe that has produced 6.0% average annual growth over ten years — and 6.0% again in 2024, remarkably steady for an industry of this size.¹But the aggregate conceals more than it reveals. Medical technology is not one market; it is several dozen, each with its own clinical driver, reimbursement mechanics, competitive structure and price dynamic. The chart below shows the ten segments most often sized by commercial research — ten separate forecasts, each at its own horizon, so what it can honestly say is relative scale and where growth sits: diabetes care is the fastest-growing of the ten, and in 2024 the industry as a whole split into a fast lane — AI-assisted diagnostics, wearables and minimally invasive instrumentation growing at 12–22% — and a slow lane of imaging and surgical instruments at 3–6%.^24,25

Ten commercial forecasts of global segment size, each at its own horizon (2029–2031) and scope. Indicative of relative scale only — not additive, and not a ranking at a common date.²⁵

Segment structure also determines who competes. In vitro diagnostics, cardiovascular devices and orthopaedics are dominated by global strategics with the scale to absorb regulatory fixed costs. Specialty diagnostics, interventional instrumentation and technically complex niche devices are not — and that is where founder-led European manufacturers hold defensible clinical positions without the capital structure to exploit them.

2. introduction

One market on paper. Several in practice.

Germany, France, the United Kingdom, Italy and Spain are Europe's five largest national markets. Around 38,000 companies operate across them, with roughly 90% employing fewer than fifty people. Demand is supported by public healthcare budgets that are relatively stable and shaped by demographic needs.

Across Europe, health systems spend 10.4% of GDP on healthcare, 81% of this spending is publicly financed, and medical technology accounts for 7.7% of total healthcare expenditure, equivalent to less than 1% of GDP.¹,⁴

Beneath the aggregate, each segment has its own clinical driver, reimbursement mechanics, competitive structure and price dynamic. No free, authoritative source breaks the European market into clinically meaningful segments on a consistent basis, and the commercial estimates that do so diverge from one another by 15% or more, often while defining their scope inconsistently. Rather than publish a single aggregate of doubtful provenance, we set out three representative segments: orthopaedics, diabetes technology and cardiovascular, each with its own sources, its own reference year, and, where relevant, its own uncertainty band.

1

Ageing populations

widen the patient pool and lengthen the years spent under clinical management.

2

Chronic
disease

converts single acute events into multi-year cycles of implant, follow-up, replacement and comorbidity.

3

Workforce shortage

makes technologies that remove clinician time from a pathway non-optional.

4

Regulatory frameworks

raise the fixed cost of market presence and favour scale.

5

Clinical adoption inertia

ensures long switching cycles once a product is embedded.

6

Strategic consolidation

sustains an active exit landscape for niche specialists.

Engineering excellence in European MedTech SMEs is frequently not matched by capital structure, governance depth, or international infrastructure, creating a recurring investment opportunity that can be addressed through targeted operational and organisational development.

This structural gap between technical quality and institutional maturity is the thesis. The market has no shortage of strong companies. What is often missing is structured capital combined with sector expertise to unlock their full potential.

3. MAJOR REPRESENTATIVE SEGMENTS

Orthopaedics, diabetes technology, cardiovascular: three markets, three different answers.

These three segments are among the largest in medical technology and among the most relevant to founder-led European manufacturers. Each is sized below using the strongest evidence available, which differs from one segment to the next and is stated accordingly.

Orthopaedics — Western Europe, US$12.5 billion

The best-evidenced of the three. BMI/Fitch, the same source MedTech Europe licenses for its own market figures, puts orthopaedics and prosthetics in Western Europe at US$12.5 billion in 2023, growing 6.2% a year since 2019 and forecast to reach US$16.9 billion by 2028. The three published sub-lines tie exactly to the total in every year.² Two independent cross-checks hold. Against company filings, five manufacturers report US$36.3 billion of orthopaedic revenue, roughly 59% of the world segment, consistent with a famously consolidated market. Against procedure volumes, dividing the artificial-joints line by the EU's ~1.68 million hip and knee replacements gives about US$2,400 of implant value per procedure at manufacturer prices, roughly half US levels.³,⁴ Europe is structurally under-indexed in orthopaedics: 20.3% of the world segment against 26.4% of medical devices overall. The gap is price, not volume.

“Western Europe” is the BMI 15-country perimeter, not EU27 — the full European figure is higher. The taxonomy is customs-derived: spine, sports medicine and orthobiologics are not separately identifiable.

Diabetes technology — Europe, roughly US$7 billion

Here no published source survives scrutiny, so we built the number ourselves. No manufacturer publishes a European revenue line — Abbott, Dexcom, Medtronic, Insulet, Tandem and embecta all stop at US versus international — and the commercial estimates are arithmetically impossible: one puts European CGM at US$3.1 billion when Abbott's international diabetes revenue alone is US$4.8 billion.⁵Applying explicit Europe-share assumptions to disclosed non-US revenues, and adding estimates for private and undisclosed players, gives a central estimate of about US$7 billion for 2025, in a defensible band of US$6.0–8.5 billion. Continuous glucose monitoring is displacing test strips rather than growing alongside them. Penetration is the more informative metric: 2.7 million people live with type 1 diabetes in Europe, and insulin pump penetration among them ranges from 21.3% in Italy to 27% in the United Kingdom — the latter under a reimbursement mandate in force since 2008.^6,7

The market value is our construction and is labelled as such. Insulin pens bundled into drug prices by Novo Nordisk, Lilly and Sanofi are excluded — probably the largest European device category invisible in revenue terms.

Cardiovascular — the largest, and the least discounted

The largest and most procedurally intensive of the three. 62 million people in the EU live with cardiovascular disease; it caused 1.7 million deaths in 2022 — one in three — and cost European society over €282 billion in 2021, of which €47 billion in lost productivity. European hospitals record more than 9.2 million cardiovascular admissions a year, perform 1.11 million coronary angioplasties and more than 100,000 transcatheter aortic valve implantations.^8,9,10Four listed companies report US$44.2 billion of cardiovascular revenue — about 63% of a global segment of roughly US$70 billion, the same concentration seen in orthopaedics. Only one of them, Edwards Lifesciences, publishes a Europe line: 25.0% of global revenue, audited. Applying a 22–26% band to the global figure gives a European cardiovascular device market of US$15–18 billion in 2025, central ≈ US$17 billion. Note what that band implies: the European price discount is mild in cardiovascular (25% versus 26.4%) and severe in orthopaedics (20.3%) — patent-protected technology with a fast replacement cycle holds price in Europe; commoditised implants do not.¹¹

On Italian public procurement, cardiovascular (CND categories C plus J) is the largest device category — ahead of orthopaedic implants. Category J also contains non-cardiac active implants; treat C+J as an upper bound.

Reading across the three segments: the reference years and geographies differ by design — orthopaedics is 2023 Western Europe (15 countries), diabetes 2025 Europe (undefined by the sources, our construction), cardiovascular 2025 with EU27 clinical data. They are not the same territory and are not additive. Each figure carries its own year and perimeter next to it.

Southern Europe: a concentration of underserved healthcare SMEs

Italy and the broader Southern European market represent an exceptional concentration of technically credible, founder-led MedTech businesses. These companies combine engineering precision and clinical credibility with structural constraints that limit scalable growth. Many are profitable, yet sub-scale.

Succession pressure

Generational transitions create windows for structured capital entry, often off-market and relationship-driven. Nationally, more than a third of Italian family businesses face a leadership change within the decade, and only 13% reach a third generation.

MDR regulatory burden

EU Medical Device Regulation compliance demands governance, documentation and resources beyond most SMEs’ internal capacity. Twelve per cent of SME manufacturers have certified more than half their portfolio, against 38.8% of large companies.

Internationalisation constraints

Strong domestic revenues rarely translate into structured international expansion without commercial infrastructure and US market readiness — the gap that separates a €2,400 European implant price from its US equivalent.

4. Generic trends

Demand does not grow with the economic cycle. It grows with four structural forces acting at once.

Ageing widens the patient pool; the epidemiological shift to chronic non-communicable disease raises consumption intensity per patient; obesity and its new pharmacology are reallocating treatment between drug and procedure; antimicrobial resistance raises the unit cost of each episode of care. Each is independent of the others. It is their simultaneity — against a shrinking clinical workforce and budget-constrained payers — that makes MedTech demand substantially inelastic.¹²

Ageing — and the gap between lifespan and healthspan

Europeans live 81.7 years on average and spend 63.1 of them in good health. The 18.4-year difference is not survival; it is clinical management — diagnostics, implants, monitoring, rehabilitation, continuous care. That is precisely the MedTech categories, not acute pharmaceuticals, and the gap is not closing: life expectancy is rising faster than healthy life years. The over-65 share of the EU population is 22.0% today and projected to reach 29% by 2050; the over-80 share will multiply 2.5 times by 2100. Italy, at a median age of 49.1, is the oldest country in the Union.^12,13

Chronic disease — from acute events to multi-year cycles

43 million

1.8 million

65.6 million

22%

Non-communicable disease shifts consumption from isolated acute events to multi-year management pathways. A chronic patient does not generate an implant; they generate an implant, then repeated instrumental follow-up, then a replacement, then a comorbidity. That installed-base-plus-recurring-consumable model is the structure on which medical technology's revenue visibility rests.

Obesity and GLP-1 — measured substitution, unmeasured second-order effects

Adult obesity has more than doubled since 1990 and quadrupled among 5-to-19-year-olds; 890 million adults now live with obesity. The GLP-1 receptor agonists are reallocating obesity treatment from surgery to pharmacology, and the best evidence comes from a US clinical database of about 20 million patients with severe obesity: bariatric surgeries fell 21.6% from their 2023 peak while GLP-1 prescriptions in the same cohort rose 3.1-fold. Two further effects are plausible but not yet measured — a widening of the pool eligible for joint replacement as patients drop below BMI thresholds, and a shift toward continuous metabolic monitoring. We treat both as working hypotheses, not acquired facts.^15,16

Antimicrobial resistance — the trend that acts on unit cost, not volume

Bacterial AMR was associated with over 4.7 million deaths worldwide in 2021; one in six laboratory-confirmed infections in 2023 was resistant to standard antibiotics, and resistance is rising in over 40% of pathogen-antibiotic combinations. In the EU/EEA it causes more than 35,000 deaths a year — a burden comparable to influenza, tuberculosis and HIV combined — and the WHO projects treatment costs alone at US$412 billion a year by 2035. It pushes spend toward two technologies: rapid molecular diagnostics that turn empirical broad-spectrum therapy into targeted therapy within hours, and infection control — antibacterial coatings, advanced dressings, automated disinfection — where the avoided cost is quantifiable at ward level and therefore defensible in tender.^17,18

The regulatory clock

The European Commission proposed simplifying MDR and IVDR on 16 December 2025. The proposal is at Parliament committee stage, the Council has not reached a general approach, and adoption is unlikely before mid-2027 with application six months later. The first MDR transition cliff — class III and class IIb implantable devices — falls on 31 December 2027. For those devices, relief cannot arrive in time; and the companies least able to wait are the smallest: only 12% of SME manufacturers have certified more than half their portfolio, against 38.8% of large companies.^19,20

Reform-track dates are estimates. No institution has published a binding target for adoption or application.

A dual-speed industry

Those four forces do not lift every segment equally. In 2024 the industry split into a fast lane — AI diagnostics, wearables and minimally invasive devices, all growing at double digits — and a slow lane of imaging and surgical instruments growing at low single digits. Margin pressure is concentrated in the slow lane, and it is precisely there that sub-scale manufacturers come under the strain that produces a sale.²⁴

Reform-track dates are estimates. No institution has published a binding target for adoption or application.

The consequence — already visible in national health plans, not a forecast — is decentralisation: care moving from hospital to home, remote monitoring, and minimally invasive procedures with reduced length of stay. That is where the above-average-growth sub-sectors of MedTech concentrate.

5. market statistics and data

The numbers behind the thesis — sourced, dated, and where necessary caveated.

Europe's position, and Italy's within it

Europe = EU27 + Norway + Switzerland + UK. The European market figure is a MedTech Europe estimate at manufacturer prices, based on Fitch Solutions data.

How large-cap medtech revenue actually divides

Since no free source publishes clinical segment values, we built the view from the filings: 26 listed companies, US$352.8 billion of reported segment revenue, mapped to a common taxonomy. It is the concentrated top of the market — roughly three-fifths of world revenue — and contains none of the ~38,000 mostly-SME manufacturers. Cardiovascular is the clear number one; one dollar in nine fits no clinical category at all.³

Italy — the one complete, euro-denominated segment dataset that exists

The Ministero della Salute publishes SSN public spending on medical devices by CND category — €6.61 billion in 2023, up 6.9%, across 23 categories that reconcile to the stated total within €2,265. It is procurement consumption, not market value; but it is complete, governmental and, as far as we can find, published on no other investment website.²¹

Where the industry sits, and who owns it

Ownership data is all-SME (companies of €2–25m revenue), not medtech-specific. No medtech-specific Italian ownership dataset is published.

Reliability coding shows where the sample is close to the whole market (oligopolistic segments) and where major participants are missing. Dental reads zero only because no sampled company reports a dental segment.

How these businesses exit

For a European mid-market medtech company, an IPO is not a realistic exit route: of the eight medtech IPOs globally in 2025, none were European-listed. The market clears through trade sale and sponsor-to-sponsor in the €30m–€800m enterprise value band. Regulatory readiness rarely shows up as a higher headline multiple; it shows up as a larger share of the price paid on completion rather than deferred.^22,23

Exit landscape: sustained strategic buyer activity

The MedTech exit environment is consistently supported by large strategic acquirers — global device companies seeking technology, niche market access or geographic consolidation — alongside healthcare-focused private equity funds. Exit value is driven by international expansion, US market positioning, regulatory robustness and niche consolidation, within holding periods typically of three to five years.

PRIMARY EXIT ROUTE

Strategic MedTech acquirers

SECONDARY EXIT ROUTE

Healthcare-focused PE funds

VALUE CREATION DRIVERS

US readiness & MDR compliance

Our investment focus within healthcare.

We invest exclusively in high-end medical devices and diagnostics — technically complex segments where regulatory depth, clinical relationships and sector expertise create genuine competitive advantage. We do not invest across healthcare broadly; sector exclusivity is structural and deliberate.

Surgical & Diagnostic

Interventional

Specialised

TARGET COMPANY PROFILE

Founder-led, up to €10M EBITDA

Founder-led or family-owned MedTech SMEs with up to €10 million in EBITDA. Technically strong, commercially constrained. Typically profitable, sub-scale, and facing at least one structural inflection point — succession, MDR pressure, internationalisation, or capital structure gaps.

GEOGRAPHIC SCOPE

Italy first, European from inception

Primary deal flow originating in Italy, with selective European expansion into Switzerland, Germany, Austria and Spain. No geography is structurally excluded; execution proximity is prioritised in the first phase.

Four conversations we are always open to

Different people arrive at this page for different reasons. Tell us which one you are.

Owners and founders

START A CONVERSATION →

Advisers and intermediaries

SEND US THE TEASER →

Operators

JOIN THE NETWORK →

Investors and LPs

REQUEST THE THESIS →

SOURCES

1. MedTech Europe, The European Medical Technology Industry in Figures 2025 (Sept 2025), based on Fitch Solutions, World Medical Device Factbook 2024. Market at manufacturer prices; company and employment figures from a national-associations survey finalised March 2024, "latest year available" by country.

2. BMI / Fitch Solutions, Worldwide Medical Devices Market Forecasts, March 2024 – Western Europe, 15 countries, orthopaedics & prosthetics, US$ at manufacturer prices.

3. Company annual reports, 10-K/20-F filings and Q4 releases, fiscal years ending Sept 2025 – June 2026; internal bottom-up reconciliation.

4. OECD / European Commission, Health at a Glance: Europe 2024 (2022 reference data).5. Abbott, Dexcom, Medtronic, Insulet, Tandem, embecta – FY2025/FY2026 disclosures. Internal bottom-up estimate from disclosed non-US revenues; labelled as an estimate.

6. AMD, Annali 2025; NHS England, Hybrid closed loop technologies: 5-year implementation strategy.

7. International Diabetes Federation, IDF Diabetes Atlas, 11th ed., 2025 (IDF Europe region = 60 countries).

8. OECD & European Commission, The State of Cardiovascular Health in the European Union, 2025 (mortality 2022, cost 2021).

9. Eurostat, Surgical operations and procedures statistics, 2025 update (2023 data).

10. Second European TAVI pathway registry, EHJ Valvular and Structural Heart Disease, 2026 (2024 practice); ESC-EHRA Atlas 2025.11. Edwards Lifesciences FY2025 (Europe $1,517.5m / global $6,067.6m); Medtronic FY2025; Boston Scientific and Abbott FY2025. Global $70bn base: Fortune Business Insights (commercial estimate).

12. Eurostat, Population structure and ageing (1 Jan 2025); Mortality and life expectancy statistics (2024 provisional); Healthy life years statistics (2023).

13. OECD/EC, Health at a Glance: Europe 2024 – 65+ share projection to 2050.

14. WHO, Noncommunicable diseases fact sheet (2021 data); WHO Regional Office for Europe, 27 June 2025.

15. WHO, Obesity and overweight fact sheet (2022 data).

16. American Society for Metabolic and Bariatric Surgery, analysis of the Epic Cosmos database, 2026.

17. GBD 2021 Antimicrobial Resistance Collaborators, The Lancet, 2024; WHO, Global antibiotic resistance report 2025.

18. ECDC, burden of AMR in the EU/EEA; WHO AMR fact sheet (US$412bn projection).

19. European Commission, COM(2025) 1023 final, 16 Dec 2025; Council progress report ST 9801/26; Regulations (EU) 2023/607 and 2024/1860.

20. MedTech Europe, IVDR & MDR Survey 2024.

21. Ministero della Salute, Rapporto sulla spesa per l'acquisto di dispositivi medici, anno 2023, 12th ed., Dec 2025; ISS/EpiCentro, pacemaker and ICD analysis 2001–2023.

22. J.P. Morgan, Medtech Deal Report Q2 2026; company announcements.

23. Bain & Company, Global Healthcare Private Equity Report 2026 – disclosed value only; 2025 figures eleven months annualised.

24. State of the MedTech Industry in 2024 and Outlook for 2025 – segment growth ranges, margin pressure and workforce reductions.

25. MarketandMarkets, segment market reports via press releases, 2025–26 – ten separate reports; global scope; forecast horizons 2029–2031 as labelled. Commercial estimates: scopes and base years differ by report; figures are indicative and not additive. The haemodialysis & peritoneal dialysis figures include treatment services.

Market data as of 21 August 2026. Reviewed quarterly. Perimeters differ by segment and are stated next to each figure: orthopaedics = Western Europe (15 countries, BMI); cardiovascular clinical data = EU27; diabetes = Europe as constructed from company disclosures; IDF Europe = 60 countries.